State Board of Administration of Florida Retirement System lifted its holdings in shares of CareDx Inc (NASDAQ:CDNA) by 6.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,575 shares of the company’s stock after buying an additional 810 shares during the period. State Board of Administration of Florida Retirement System’s holdings in CareDx were worth $396,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in CDNA. Covenant Multifamily Offices LLC acquired a new stake in shares of CareDx in the 1st quarter worth approximately $32,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in CareDx during the fourth quarter valued at approximately $45,000. Pearl River Capital LLC acquired a new stake in CareDx during the first quarter valued at approximately $48,000. Great West Life Assurance Co. Can acquired a new stake in CareDx during the fourth quarter valued at approximately $81,000. Finally, Legal & General Group Plc lifted its stake in CareDx by 19.5% during the fourth quarter. Legal & General Group Plc now owns 6,129 shares of the company’s stock valued at $154,000 after purchasing an additional 998 shares during the last quarter. 88.75% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ CDNA traded up $0.02 during trading hours on Friday, hitting $35.99. 1,560,900 shares of the stock were exchanged, compared to its average volume of 822,337. The business’s 50 day moving average is $34.60. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -27.47 and a beta of 0.88. CareDx Inc has a one year low of $11.85 and a one year high of $40.50.
CDNA has been the topic of a number of recent analyst reports. BidaskClub lowered shares of CareDx from a “strong-buy” rating to a “buy” rating in a report on Friday, March 29th. Piper Jaffray Companies upped their price objective on shares of CareDx from $42.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, May 9th. HC Wainwright upgraded shares of CareDx from a “neutral” rating to a “buy” rating and upped their price objective for the company from $30.00 to $43.00 in a research note on Thursday, May 9th. Raymond James upped their price objective on shares of CareDx from $38.00 to $46.00 and gave the company a “strong-buy” rating in a research note on Friday, March 22nd. Finally, TheStreet upgraded shares of CareDx from a “d” rating to a “c” rating in a research note on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. CareDx presently has an average rating of “Buy” and a consensus price target of $40.17.
In other news, insider James P. Yee sold 20,000 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $37.54, for a total value of $750,800.00. Following the completion of the transaction, the insider now owns 62,170 shares in the company, valued at approximately $2,333,861.80. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Sasha King sold 1,250 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $29.50, for a total transaction of $36,875.00. Following the sale, the insider now owns 77,427 shares of the company’s stock, valued at approximately $2,284,096.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 188,888 shares of company stock valued at $6,367,597. Insiders own 3.20% of the company’s stock.
CareDx Company Profile
CareDx, Inc operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Recommended Story: Futures Contract
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.